|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Detection of B-raf exon 15 mutations or prediction of the activating mutation V599E were not statistically associated with the risk for subsequent metastasis in the follow-up of patients.
|
15331929 |
2004 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
However, RAF inhibitors paradoxically accelerate metastasis in RAS-mutant tumors and become ineffective in BRAF(V600E) tumors because of reactivation of downstream mitogen-activated protein kinase (MAPK) signaling.
|
25097033 |
2014 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Thirty-three samples (7 of 25 primaries, 15 of 25 regional metastases, 5 of 25 nodal metastases, and 6 of 10 distant metastases) harbored the V599E B-RAF mutation (39%), 12 contained a Q61R N-RAS mutation and 5 a Q61K N-RAS mutation.
|
14695143 |
2003 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The BRAF (V600E) mutation was associated with aggressive clinical behaviors including extrathyroid invasion, lymph nodal metastasis and tumor multifocality.
|
23179992 |
2013 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We observed mutations resulting in the V599E amino-acid substitution in 41 of 60 (68%) melanoma metastases, 4 of 5 (80%) primary melanomas and, unexpectedly, in 63 of 77 (82%) nevi.
|
12447372 |
2003 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here, we show intralesional molecular heterogeneity in a progressing V600E BRAF-mutant melanoma metastasis from a patient treated for 7 months with the BRAF inhibitor vemurafenib.
|
22962325 |
2012 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Univariate analysis indicated that BRAF((V600E)) was associated with greater tumor size (P=0.0048), extra-thyroid invasion (P<0.0001), and cervical lymph nodal metastases (P=0.0001).
|
18310287 |
2008 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The utility of immunohistochemistry (IHC) as an alternative approach for detection of BRAF(V600E) in the thoracic metastases of sporadic mCRC patients has not been evaluated until now.
|
24798160 |
2014 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our results provide support for the role of BRAF(V600E) in metastasis and suggest that inhibiting invasion is a potential therapeutic strategy against melanoma.
|
27210749 |
2016 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This is the largest study on the aggressive role of TERT promoter mutations in ATC, demonstrating an association of TERT C228T with BRAF V600E, older patient age, and tumor distant metastasis in ATC.
|
25584719 |
2015 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion.
|
22105775 |
2012 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
All four patients with distant metastasis had BRAF(V600E) mutation.
|
22767446 |
2012 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
After controlling for the effect of MS status, there was no correlation of RNF43 frameshift mutation with distant metastasis (OR = 1.57 [0.75, 3.28]) and advanced TNM stages (OR = 0.98 [0.58, 1.67]), but RNF43 frameshift mutations still occur more frequently in right colon (OR = 2.58 [1.49, 4.47]) and with BRAF V600E mutation (OR = 1.94 [1.22, 3.10]).
|
31122752 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Sixty-eight samples (20 of 36 primaries, 18 of 27 regional metastases, 16 of 40 nodal metastases, and 9 of 12 distant metastases) harbored the V599E B-RAF mutation (59%), 17 contained a Q61R N-RAS mutation, and 4 contained a Q61K N-RAS mutation.
|
15737846 |
2005 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
There was no significant correlation with BRAF (V600E) mutation and age, gender, tumor size, ETE, central lymph node metastasis, the status of pT, pN1a-b, and distant metastasis.
|
26951110 |
2016 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Therefore, we established a large collection of patient-derived xenografts (PDXs), derived from BRAF(V600E), NRAS(Q61), or BRAF(WT)/NRAS(WT) melanoma metastases prior to treatment with BRAF inhibitor and after resistance had occurred.
|
27320919 |
2016 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In malignant FNABs, BRAF(V600E) mutation was significantly associated with presence of extra-thyroidal extension and metastases after surgery.
|
21948220 |
2011 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We also studied the role of BRAF V600E mutation in a set of melanoma patients who had been investigated for sentinel node metastasis.
|
25442222 |
2015 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
One case in a 6-year-old male was morphologically similar to the BRAF V600E mutation-positive adult cases and subsequently metastasized to the lungs; remarkably, the metastases then completely resolved on Braf targeted therapy.
|
31192863 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Analysis of the metastatic tumor demonstrated clonal expansion of a BRAF V600E subpopulation.
|
29744614 |
2018 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Concordance in BRAF V600E status over time in malignant melanoma and corresponding metastases.
|
29119584 |
2018 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF(V600E) mutation is predictive for distant metastasis in papillary thyroid carcinoma but not positively.
|
23981603 |
2013 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In this study, the occurrence and percentage of the BRAF V600E mutated allele was not preferentially associated with the development of metastases and the average mutated allele percentage decreased as the tumor progresses from the primary site to the lymph node metastatic sites.
|
23533235 |
2013 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
dMMR and BRAF V600E mutations were identified in 31 of 208 (14.9%) and 23 of 211 (10.9%) tumors, respectively. dMMR was more commonly found in patients with primary colon tumors rather than rectal cancer (20.4% vs 7.6%, P =0.01), but there was no difference in MMR status between the right-sided and left-sided colon tumors (20.8% vs 34.6%, P = 0.24). dMMR was associated with early-stage rather than metastatic disease (17.3% vs 0%, P = 0.015).
|
25624727 |
2015 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
They include BRAF(V600E) and AKT that affect tumor initiation, progression and metastasis.
|
24362526 |
2014 |